We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Dilon Diagnostics Partners with PenRad for Diagnostic Imaging and Information Management Technology

By MedImaging International staff writers
Posted on 12 Sep 2011
Print article
Dilon (Newport News, VA, USA) expands its range of breast imaging systems through a sales alliance with PenRad (Minnetonka, MN, USA). Together, Dilon and PenRad provide sophisticated breast imaging tools, and an information management system that significantly improves patient care, mammography workflow, and imaging center economics.

Dilon Diagnostics is a market leader for compact gamma cameras that support breast-specific gamma imaging/molecular breast imaging (BSGI/MBI) studies. Dilon optimizes the clinical results of BSGI/MBI, a procedure that sees lesions independent of tissue density and provides a functional imaging complement to the anatomical imaging of mammography. BSGI/MBI is particularly useful for patients with equivocal mammograms, dense breast tissue and for help with determining the extent of disease.

With camera installations worldwide, Dilon is now expanding its product range in women’s imaging to include the PenRad mammography information system (MIS), and Volpara, a quantitative breast density-assessment tool that converts the qualitative breast X-ray image into quantitative data. Breast tissue density has not only been tied to an increased risk of breast cancer, it also decreases the sensitivity of the mammogram and thereby may impact early detection. Volpara is designed to assist radiologists by assessing a woman’s breast density objectively and automatically, and facilitates breast centers’ compliance with new legislation and notification guidelines. PenRad automatically integrates the information from Volpara and BSGI/MBI into the routine MIS workflow.

PenRad has been pioneering the technologic advancement of MIS for 15 years, increasing professional productivity, reducing costs, and enhancing patient care.

CEO of Dilon Diagnostics, Robert G. Moussa, said, “Dilon’s expanded suite of PenRad MIS products align well with our global strategy of providing diagnostic solutions with the most sophisticated technological platforms. Our vision is to provide patients and physicians around the world with superior, cost-effective, and healthcare solutions that provide the greatest opportunity for early diagnosis and intervention for breast cancer.”

PenRad’s range of products provides a complete solution to enhance workflow, quality, and revenue in image and information management. Designed flexible and for easy integration, PenRad products include a Web-based, multimodality workstation, computer-aided visualization, and analysis for magnetic resonance imaging (MRI) and computer-aided detection (CAD) for ultrasound, and information systems for fast and effective interpretation, reporting, tracking, and management of clinical data. Whether integrating with existing infrastructure or providing a complete solution, PenRad partners with customers to optimize workflow.

Dilon Diagnostics, a brand of Dilon Technologies, Inc., is bringing innovative medical imaging products to the global medical marketplace. Dilon’s cornerstone product, the Dilon 6800, is a digital high-resolution, compact gamma camera optimized to perform BSGI, a molecular breast imaging procedure, which images the metabolic activity of breast lesions through radiotracer uptake, indicating the presence or absence of a cancer.

Related Links:

Dilon
PenRad



Multi-Use Ultrasound Table
Clinton
Silver Member
X-Ray QA Meter
T3 AD Pro
3T MRI Scanner
MAGNETOM Cima.X
X-ray Diagnostic System
FDX Visionary-A

Print article

Channels

Radiography

view channel
Image: AI can identify “mammographically-visible” types of interval cancers earlier by flagging them at the time of screening (Photo courtesy of ScreenPoint Medical)

AI Improves Early Detection of Interval Breast Cancers

Interval breast cancers, which occur between routine screenings, are easier to treat when detected earlier. Early detection can reduce the need for aggressive treatments and improve the chances of better outcomes.... Read more

Nuclear Medicine

view channel
Image: In vivo imaging of U-87 MG xenograft model with varying mass doses of 89Zr-labeled KLG-3 or isotype control (Photo courtesy of L Gajecki et al.; doi.org/10.2967/jnumed.124.268762)

Novel Radiolabeled Antibody Improves Diagnosis and Treatment of Solid Tumors

Interleukin-13 receptor α-2 (IL13Rα2) is a cell surface receptor commonly found in solid tumors such as glioblastoma, melanoma, and breast cancer. It is minimally expressed in normal tissues, making it... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.